| Catalog Number CS-O-00859 |
|
| CAS Number 67346-49-0 |
|
| Status Available for immediate dispatch |
|
| Category API Standards |
|
| Purity 99.04 |
|
| Molecular Weight 344.4 mol/gt |
|
Hazardous Compound |
|
| Controlled Substance No |
|
| Application "Arformoterol is a long-acting beta-2 adrenergic agonist and isomer of formoterol with bronchodilato... |
|
| Synonyms "(R,R)-Formoterol"... |
|
| References "Brovana Prescribing information, Dosage and Administration section13 February 2008," |
|
| IUPAC Name N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide |
|
| Exact Mass 344.17360725 |
|
| Solubility In water, 1.12X10+4 mg/L at 25 °C /Estimated/ |
|
| Hazard Class Acute Tox. 4 (23.08%) |
|
| Description Arformoterol is an N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide in which both of the stereocentres have R configuration. The active enantiomer of formoterol, it is administered by inhalation (generally as the tartrate salt) as a direct-acting sympathomimetic and bronchodilator for the treatment of chronic obstructive pulmonary disease (any progressive respiratory disease that makes it harder to breathe over time, such as chronic bronchitis and emphysema). It has a role as a bronchodilator agent, an anti-asthmatic drug and a beta-adrenergic agonist. It is a conjugate base of an arformoterol(1+). It is an enantiomer of a (S,S)-formoterol. |
|
| Vapor Pressure 5.0X10-14 mm Hg at 25 °C /Estimated/ |
|
| Toxicity Summary A death was reported in dogs after a single oral dose of 5 mg/kg (approximately 4500 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis). As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose. |
|
| Antidoteand Emergency Treatment There is no clinical experience on the management of overdose. Treatment should be symptomatic and supportive. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. Cardiac monitoring is recommended. There is insufficient evidence to determine if dialysis is beneficial for overdosage of formoterol. |
|
| Human Toxicity Excerpts /SIGNS AND SYMPTOMS/ As with other inhaled beta2-receptor agonists, a patient may develop acute bronchospasm, which may be life-threatening, immediately upon inhalation of formoterol. If paradoxical bronchospasm occurs, formoterol should be discontinued immediately and alternative therapy instituted. |
|